GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab ...

Here’s what you need to know. While most people who contract RSV can recover at home, some are sick enough to be admitted to ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

The Pan American Health Organization said it will provide countries in the Americas with affordable access to respiratory ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.